The 116th AACR Annual Meeting will be held from April 25 to 30, 2025, at the McCormick Place Convention Center in Chicago, USA. Among the 6,470 abstracts released for the 2025 AACR, there are 340 related to antibody-drug conjugates (ADCs), covering various types such as single-target ADCs, dual-target ADCs, and dual-payload ADCs. These involve numerous […]
In 2024, the radiopharmaceutical sector has seen a flurry of activity in mergers and acquisitions. In March, AstraZeneca announced a $2.4 billion acquisition of Fusion Pharmaceuticals, a biopharmaceutical company focused on developing next-generation radiolabeled conjugates (RDCs). In April, Novartis invested nearly $2.71 billion to partner with PeptiDream to co-develop several macrocyclic-targeted conjugate radiopharmaceuticals. In May, Novartis made […]
On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and commercialize uliledlimab in Greater China. This partnership, valued at approximately €213 million (around 1.7 billion RMB), aims to leverage Sanofi’s expertise in oncology to accelerate the development and commercialization of uliledlimab, which is an innovative CD73 monoclonal antibody independently developed […]
On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a potentially first-in-class antibody-drug conjugate (ADC) targeting HER3, has met its primary endpoint for progression-free survival (PFS) in the Phase 3 lung cancer trial HERTHENA-Lung02. This treatment demonstrated statistically significant improvement compared to platinum-based chemotherapy combined with pemetrexed induction and pemetrexed […]
According to a blog released by market intelligence provider Future Market Insights, Inc. (FMI) on September 12 this year, the global market for systemic lupus erythematosus (SLE) drugs is showing significant growth, with surprising acceleration. FMI predicts that the SLE drug market will experience robust expansion in the coming years. In 2020, the market was […]
On August 27, 2024, Legend Biotech’s BCMA CAR-T product, Carvykti® (generic name: ciltacabtagene autoleucel injection), received approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). Previously, under Johnson & Johnson’s leadership, Carvykti had already been introduced in the United States, the European Union, […]
Do you remember the temperature and touch receptor TRPV1 that made American scientists David Julius and Ardem Patapoutian accessible to the Nobel Prize in Physiology or Medicine in 2021? Transient Receptor Potential Vanilloid 1 (TRPV1) has gained significant attention in the field of pain treatment due to its potential as a therapeutic target. However, as […]
On July 16, 2024, Dr. Roger Cone, co-founder of the preclinical biotech company Courage, published a study in The Journal of Clinical Investigation titled “Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice.” The research demonstrated the synergistic effect between GLP-1 receptor agonists (GLP1RA) and MC4R agonists, revealing that low […]
The B cell maturation antigen (BCMA), a target that gained prominence due to its association with multiple myeloma, has recently shown significant progress in the treatment of autoimmune diseases. On May 10, 2024, a research team led by Wang Wei from the Department of Neurology at Tongji Hospital, Tongji Medical College, Huazhong University of Science […]
Currently, the most popular GLP1-based monotherapy, Semaglutide, controls blood sugar by promoting insulin secretion and induces a lasting sense of fullness to reduce appetite. However, this drug can cause side effects such as nausea and vomiting, which can affect patient adherence to the treatment. On July 10, 2024, Kuei-Pin Huang and colleagues published a paper […]